UBS Group Issues Pessimistic Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price target decreased by equities research analysts at UBS Group from $260.00 to $255.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. UBS Group’s target price indicates a potential upside of 22.97% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. TD Cowen dropped their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. The Goldman Sachs Group cut their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Stock Down 1.2 %

IQV stock traded down $2.60 during midday trading on Friday, hitting $207.36. 216,221 shares of the company’s stock were exchanged, compared to its average volume of 1,378,248. The stock has a market capitalization of $37.64 billion, a price-to-earnings ratio of 27.24, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a 50 day moving average price of $200.53 and a 200-day moving average price of $219.80. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. On average, analysts anticipate that IQVIA will post 10.18 EPS for the current year.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently modified their holdings of the stock. Capital Performance Advisors LLP bought a new position in IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at $33,000. Avior Wealth Management LLC increased its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in shares of IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after purchasing an additional 99 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.